KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Cash & Equivalents (2016 - 2025)

Medpace Holdings (MEDP) has disclosed Cash & Equivalents for 11 consecutive years, with $285.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 56.56% year-over-year to $285.4 million, compared with a TTM value of $285.4 million through Sep 2025, down 56.56%, and an annual FY2024 reading of $669.4 million, up 172.74% over the prior year.
  • Cash & Equivalents was $285.4 million for Q3 2025 at Medpace Holdings, up from $46.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $669.4 million in Q4 2024 and bottomed at $28.3 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $271.6 million, with a median of $285.4 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents crashed 93.87% in 2022, then surged 1205.37% in 2024.
  • Year by year, Cash & Equivalents stood at $461.3 million in 2021, then plummeted by 93.87% to $28.3 million in 2022, then soared by 768.38% to $245.4 million in 2023, then soared by 172.74% to $669.4 million in 2024, then crashed by 57.37% to $285.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for MEDP at $285.4 million in Q3 2025, $46.3 million in Q2 2025, and $441.4 million in Q1 2025.